logo     small logo upcfbih    

Herceptin

  • Core biopsy of the ER+ breast cancer in the patient under chemotherapy+Herceptin (Her2 3+)

     IMG 0282 IMG 0283 
     Figure 1. H&E, 5x. Figure 2. H&E, 5x. (note the inflammatory response within the myxoid stroma and residual DCIS) 
    IMG 0284  IMG 0285 
     Figure 3. H&E, 5x. Figure 4. H&E, 10x.
    IMG 0286 IMG 0287
    Figure 5. H&E, 10x. Figure 6. H&E, 20x.
    IMG 0288  
    Figure . H&E, 20x.  
  • Mucinous carcinoma of the breast (type B, ER+/PR-/Her2 3+) with chemoresistance (Herceptin)

     IMG 0091 IMG 0092 
     Figure 1. Her2 overexpression in the tumor cells (after neoadjuvant chemoterapy + Herceptin) Figure 2. Her2 overexpression in the tumor cells (after neoadjuvant chemoterapy + Herceptin) 
     IMG 0093  
     Figure 3. Some tumor cells showed 2+ Her2 positivity.  
  • Type B Mucinous Carcinoma (Breast)

    Figure 1 5x Figure 2 5x 
     Figure 1. H&E, 5x. Figure 2. H&E, 5x.
     ER expression 5x Her2 expression 5x 
     Figure 3. The tumor cells were negative for estrogen receptor (ER); note the positive control in the adjacent normal duct epithelium (5x). The tumor cells were also PR negative (not shown). Figure 4. The tumor cells were positive for HER-2/neu receptor (scores 2+ and 3+ in >10% of tumor cells); note the lack of HER-2/neu expression in the adjacent normal duct epithelium (5x). 

Newsletter

Sign up for news from our website (announcements, availability of program and course materials; 2-5 emails per year).